Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Paclitaxel-induced lupus].

Alain Lortholary1, Myriam Cary-Ten Have Dallinga, Claude El Kouri

  • 1Service de chimiothérapie, Centre Catherine de Sienne, Nantes. lortholary.alain@catherinedesienne.fr

Presse Medicale (Paris, France : 1983)
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Blood advances·2026
Same author

Prevalence of the Predisposing Gene MBD4 for Uveal Melanoma.

JAMA ophthalmology·2026
Same author

Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.

Gut microbes·2026
Same author

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances·2026
Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026
Same author

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Paclitaxel, a common cancer drug, can induce lupus, a condition not previously linked to this treatment. This case report details a patient who developed lupus twice while receiving paclitaxel for ovarian cancer.

Area of Science:

  • Oncology
  • Rheumatology
  • Dermatology

Background:

  • Paclitaxel (Taxol) is a vital chemotherapy agent derived from the Pacific yew tree, extensively used for treating various cancers like ovarian, breast, and lung.
  • Lupus is a chronic autoimmune disease with diverse clinical manifestations.
  • A causal link between paclitaxel and lupus induction has not been previously established in medical literature.

Observation:

  • A case study involving a female patient with ovarian cancer is presented.
  • The patient experienced the onset of lupus symptoms on two separate occasions during paclitaxel treatment.
  • Remarkably, paclitaxel demonstrated significant efficacy in managing the patient's ovarian cancer during both treatment episodes.

Findings:

  • The diagnosis of lupus was substantiated by characteristic skin lesions, elevated antinuclear antibody titers, and confirmed by skin biopsy.

Related Experiment Videos

  • The lupus symptoms recurred upon reintroduction of paclitaxel, strongly suggesting a causal relationship.
  • This represents the first documented instance of paclitaxel-induced lupus.

    • Implications:

    • This case highlights a potential, previously unrecognized adverse effect of paclitaxel therapy.
    • Clinicians should remain vigilant for lupus development in patients undergoing paclitaxel treatment, particularly those with autoimmune predispositions.
    • Further research is warranted to elucidate the mechanisms underlying paclitaxel-induced lupus and to inform clinical management strategies.